Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/28/2025 | $120.00 | Overweight | Analyst |
12/11/2024 | $103.00 → $120.00 | Equal Weight → Overweight | Wells Fargo |
6/28/2024 | $96.00 | Outperform | Robert W. Baird |
4/11/2024 | $88.00 | Buy | CL King |
2/7/2024 | $87.00 | Neutral | BofA Securities |
12/21/2023 | $100.00 | Hold → Buy | Canaccord Genuity |
12/20/2022 | $73.00 → $72.00 | Buy → Hold | Canaccord Genuity |
2/25/2022 | $73.00 → $72.00 | Outperform | Raymond James |
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
10-K/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
DEFA14A - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
DEF 14A - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r
SOUTH JORDAN, Utah, April 09, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader in healthcare technology, today announced the US commercial release of its Ventrax Delivery System. The new delivery system is Merit's latest addition to its growing electrophysiology (EP) and cardiac rhythm management (CRM) portfolio. The portfolio provides a unique selection of solutions to improve cardiac interventions, including the HeartSpan®, Worley™, Prelude SNAP™, and SafeGuard Focus® product lines. Ventrax is intended to facilitate placement of devices used in ablation procedures commonly performed to treat an abnormally fast heartbeat known as ventricular tachycardi
SOUTH JORDAN, Utah, April 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2025, after the close of the stock market on Thursday, April 24, 2025. Merit plans to hold its investor conference call on the same day (Thursday, April 24, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed us
SOUTH JORDAN, Utah, March 27, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, announced today that the American Society for Gastrointestinal Endoscopy (ASGE) updated its guideline on the diagnosis and management of gastroesophageal reflux disease (GERD) to include Transoral Incisionless Fundoplication (TIF 2.0) and TIF 2.0 Consecutive Transoral Incisionless Fundoplication (cTIF)* procedures as evidence-based approaches to care. GERD occurs when stomach acid flows into the esophagus, causing irritation of the tissue lining. Uncomfortable symptoms can include heartburn, upper stomach or chest pain, trouble swallowing, and chronic
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
Analyst initiated coverage of Merit Medical with a rating of Overweight and set a new price target of $120.00
Wells Fargo upgraded Merit Medical from Equal Weight to Overweight and set a new price target of $120.00 from $103.00 previously
Robert W. Baird initiated coverage of Merit Medical with a rating of Outperform and set a new price target of $96.00
SOUTH JORDAN, Utah, April 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2025, after the close of the stock market on Thursday, April 24, 2025. Merit plans to hold its investor conference call on the same day (Thursday, April 24, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed us
Fourth Quarter Highlights† Reported revenue of $355.2 million, up 9.4%Constant currency revenue* and constant currency revenue, organic* up 10.1% and up 6.1%, respectivelyGAAP operating margin of 10.3%, compared to 10.4% in prior year periodNon-GAAP operating margin* of 19.6%, compared to 16.6% in prior year periodGAAP EPS $0.46, down 2.6%,Non-GAAP EPS* $0.93, up 25.8%, andFree cash flow* generation of $65.3 million, up 18.4% Fiscal Year 2024 Highlights† Reported revenue of $1.357 billion, up 7.9%Constant currency revenue* and constant currency revenue, organic* up 8.5% and up 6.0%, respectivelyGAAP operating margin of 11.5 %, compared to 9.9% in prior yearNon-GAAP opera
2024 preliminary unaudited revenue in the range of approximately $1.355 billion - $1.357 billion, up approximately 7.7% - 7.9% year-over-year2024 preliminary constant currency revenue* increased in the range of approximately 8.4% - 8.6% year over year2024 financial results and 2025 guidance to be released February 25, 2025 * Constant currency revenue is a non-GAAP financial measure. A reconciliation of this financial measure to its most directly comparable GAAP financial measure is included under the heading "Non-GAAP Financial Measure" below. SOUTH JORDAN, Utah, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of hea
SOUTH JORDAN, Utah, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) ("Merit" or the "Company"), a global leader of healthcare technology, today announced the resignation of its President, Joseph C. Wright, effective January 3, 2025. The Company noted that prior to Mr. Wright's resignation, Merit had received notice of allegations regarding his conduct, which Merit's independent directors investigated with the assistance of independent counsel. The allegations were unrelated to Merit's operations or financial performance. Based upon Mr. Wright's resignation, Merit's Board of Directors has re-appointed Fred P. Lampropoulos as Merit's President. ABOUT MERI
SOUTH JORDAN, Utah, May 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced that its shareholders elected Silvia M. Perez, President of the Commercial Branding and Transportation Division at 3M Company, as a director in Merit's Annual Meeting of Shareholders held on May 15, 2024. Merit's shareholders also re-elected Fred P. Lampropoulos and Stephen C. Evans as directors. Ms. Perez and Messrs. Lampropoulos and Evans were elected to serve three-year terms. "We are pleased to welcome Silvia Perez as our newest director," said Mr. Lampropoulos, Merit's Chairman and Chief Executive Officer. "Her expertise and proven
Joe Wright Appointed President Expands Deep Bench of Leadership Team Talent; Supports "Continued Growth Initiatives" Program SOUTH JORDAN, Utah, May 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced the appointment of Joe Wright as President, effective immediately. As President, Mr. Wright will be responsible for the oversight of Merit's global commercial, marketing, and manufacturing operations. Mr. Wright has been an instrumental part of the Merit team over the past 19 years. He most recently served as Chief Commercial Officer, where he led the development and expansion of Merit's global commercial activit